Niox Flex a Nitric Oxide Monitoring System

Aerocrine is proud to announce the introduction of NIOX Flex!

NIOX Flex is the successor of NIOX, the first tailor-made Nitric Oxide Monitoring System for routine clinical use in asthma patients. NIOX Flex measures NO in exhaled air according to ATS/ERS FE_NO guidelines.

NIOX Flex measures FE_NO, fractional exhaled nitric oxide, to evaluate responsiveness of anti-inflammatory therapy in asthma patients. Put simply, NIOX Flex lets you see more than your asthma patients can tell you.

NIOX Flex uses the high sensitivity and specificity of a chemiluminescence gas analyzer, together with integrated software, to accurately measure NO molecules at very low concentrations.

Despite the advanced technology employed, the device is very easy to use and is suitable not only for adults, but also for children age 4 and up.

Do you already have a NIOX system? Rebuild your NIOX to a NIOX Flex!

Aerocrine AB is a clinically based medical technology corporation dedicated to improved asthma management and care. The company is marketing NIOX^® Flex on a worldwide basis and is also marketing NIOX MINO^®, representing a new generation of hand-held devices, in Europe. Both products are tailored for rapid, non-invasive control of the inflammatory status in the airways and may play a critical role for a more efficient diagnosis, treatment and monitoring of asthma patients.

Aerocrine is located in Sweden with wholly owned subsidiaries in the US, UK and Germany.

More information about Aerocrine and nitric oxide as an inflammatory marker.